People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...
PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targe ...
President Trump’s nominee to head the Department of Health and Human Services, Robert Kennedy Jr., will soon go before the ...
The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
"We are pleased the FDA has accepted our NDA for Bumetanide Nasal Spray," said Benjamin Esque, CEO of Corstasis Therapeutics ...
WOOD Grand Rapids on MSN3d
Nose spray to treat depression? FDA approves first-of-its-kind medicineThe U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...
Health and Me on MSN5d
Seasonal Allergies Troubling You? Try These Natural AntihistaminesIn people prone to allergies, exposure to pollen and allergens triggers the release of histamine—a chemical responsible for ...
The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback